HC Wainwright & Co. Reiterates Neutral on CytomX Therapeuticsto Neutral

Benzinga · 01/07 11:32
HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Neutral.